34 results about "Gallbladder cancer" patented technology

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

Abstract The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 2020220128 20 Aug 2020

The application finds that SDF4 in a body fluid sample can become a marker for detecting cancer patients with good sensitivity and specificity. By using a reagent for specifically detecting SDF4, gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, liver cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer can be detected. The measurement of SDF4 in a body fluid sample is a detection method capable of detecting various cancers by a single test, and can be used for large-scale screening of cancers. In addition, early-stage cancers can be detected with good sensitivity and specificity, so that cancers can be found and treated in an early stage.

The invention discloses a human gallbladder cancer cell line and application thereof. The human gall bladder cancer cell line comprises a human gall bladder cancer cell JXQ-3D-8529R1 or a human gall bladder cancer cell JXQ-3D-8529R2; the human gallbladder cancer cell JXQ-3D-8529R1 is preserved in the China Center for Type Culture Collection, and the preservation number of the human gallbladder cancer cell JXQ-3D-8529R1 is CCTCC NO: C2023372; the preservation number of the human gallbladder cancer cell JXQ-3D-8529R2 is CCTCC (China Center For Type Culture Collection) NO: C2023371. The human gallbladder cancer cells JXQ-3D-8529R1 and JXQ-3D-8529R2 can be massively amplified, can be subcultured in vitro for a long time, have different sensitivities to cis-platinum, gemcitabine and the like, enrich a human gallbladder cancer cell bank, and provide a new test material for revealing the occurrence and development mechanism of gallbladder cancer and preclinical research of corresponding drug development.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

This invention discloses a method for fabricating a memristor based on a bile functional layer, belonging to the field of bioelectronic device fabrication and in vitro diagnostics of biliary tract diseases. The method sequentially completes FTO substrate pretreatment, bile functional layer preparation, Ag-on-electrode deposition, and memristor detection array fabrication. First, the FTO substrate is physically cleaned and plasma-activated. Then, a 240-260 nm bile functional layer is prepared. Subsequently, an Ag-on-electrode is deposited, and a 5-15 nm Ag atom embedding transition region is constructed. Finally, a 2×2 array is arranged and passivated for isolation. The process parameters of each step are synergistically matched to optimize the interface between the substrate, functional layer, and electrode, fully preserving bile pathological information. The resulting Ag / Bile / FTO structure memristor exhibits high electrical stability and shows significant differences in electrical response to bile samples from normal, gallstone, and gallbladder cancer patients. It enables accurate and rapid in vitro identification of biliary tract diseases, and the process is simple, low-cost, and suitable for clinical application and large-scale production.

The application relates to the field of biological medicines, and particularly relates to a long-chain non-coding RNA (lncRNA) encoded short peptide and corresponding monoclonal antibody, the short peptide is encoded by long-chain non-coding RNA LOXL1-AS1 and is named PEPLA, research shows that PEPLA is highly specifically expressed in gallbladder cancer tissues and has a significant difference compared with normal tissues, based on this, a recombinant expression method of PEPLA is provided, and a monoclonal antibody taking PEPLA as an antigen is constructed, the monoclonal antibody can specifically recognize PEPLA, and is further applied to the diagnosis, prognosis evaluation and targeted treatment of gallbladder cancer, the technology provides a new molecular target for early diagnosis and precise treatment of gallbladder cancer, and has a wide clinical application prospect.

This application discloses the application of PLAC8 as a target in the preparation of tumor therapeutic drugs, involving the field of biomedical technology. This application clarifies that the "sympathetic nervous system-β2-AR-PLAC8-cholesterol metabolism-M2 polarization" pathway is the core driving pathway for stress-related tumor progression and chemotherapy resistance. It reveals the molecular mechanism by which PLAC8 inhibits cholesterol synthesis through phosphorylation at the S67 site, binding to the N-terminal domain of SREBP2, recruiting OGT to mediate SREBP2O-GlcNAc glycosylation. Through strategies such as gene silencing, β2-AR antagonist intervention, and targeted delivery of siPLAC8 via mannose-modified lipid nanoparticles (LNPs), the application achieved the effects of inhibiting M2 macrophage accumulation, inhibiting tumor growth, and reversing chemotherapy resistance in various tumor models, including gallbladder cancer, intrahepatic cholangiocarcinoma, and prostate cancer. Furthermore, the LNPs delivery system showed no significant toxicity. This research provides a novel therapeutic target centered on PLAC8 and a safe and effective targeted intervention strategy for stress-related tumors, highlighting its clinical translational value.

The present invention relates to the field of medical technology and is a method for preparing an ultrasensitive electrochemical immunosensor for specifically detecting CTCs in gallbladder cancer. The method comprises the following steps: a. synthesizing SiO2 nanospheres; b. synthesizing SiO2@QD using the SiO2 nanospheres synthesized in step a; c. preparing SiO2@QD-Ab using the SiO2@QD synthesized in step b; and d. constructing an immunoelectrochemical platform using the SiO2@QD-Ab synthesized in step c. The present invention also discloses a method for applying the ultrasensitive electrochemical immunosensor for specifically detecting CTCs in gallbladder cancer. The method exhibits high sensitivity, high specificity, low cost, and rapid detection speed.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

The invention relates to the technical field of molecular biology and medical detection, and particularly discloses a group of gallbladder cancer plasma exosome microRNAs markers as well as a detection method and application of the gallbladder cancer plasma exosome microRNAs markers, and the markers comprise at least one of miR-135b-5p, miR-224-5p, miR-451a, miR-148a-3p and miR-375-3p. The marker combination shows a characteristic expression profile (two-liter and three-drop) in gallbladder cancer patients; the invention provides a non-diagnostic purpose detection method of the marker, efficient and non-invasive identification of gallbladder cancer is realized by optimizing an exosome separation and detection process and constructing a combined diagnosis model, the AUC reaches 0.987, the sensitivity is 93.3%, and the specificity is 91.7%; the marker and the method can be used for preparing a detection kit related to gallbladder cancer, and have important clinical application value.

The present application belongs to the field of biomedicine. Disclosed are an siRNA for inhibiting KRAS gene expression, and a modified form thereof and the use thereof. Provided in the present application is a double-stranded RNA molecule targeting KRAS, wherein the molecule can treat KRAS-associated diseases such as metastatic non-small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, KRAS G12C+ non-small cell lung cancer, diabetic retinopathy, leukemia, cholangiocarcinoma, metastatic colorectal cancer, gastric cancer, advanced non-small cell lung cancer, stage-IV non-small cell lung cancer, gastric adenocarcinoma, sepsis, KRAS G12C-mutated advanced non-small cell lung cancer and gallbladder cancer.

The present invention discloses a magnetic resonance-guided focused microwave brain tumor thermal ablation system and a focusing adjustment method. The present invention integrates the three-dimensional data of MRI and CT, selects the microwave frequency suitable for the size and depth of the tumor, and designs a suitable antenna and a cross-polarized antenna phased array. The differential evolution algorithm is used to optimize the antenna output power and phase to achieve precise focusing of microwave energy, increase the tumor temperature to the ablation level, and maintain the safe temperature of healthy tissue. The system effectively suppresses the adverse effects of brain tissue, including the skull, on microwave penetration, and achieves precise ablation of tumors through a small number of antennas combined with an iterative algorithm. Combined with MRI guidance and real-time temperature monitoring, the accuracy and safety of thermal ablation are ensured, non-invasive radical treatment of brain tumors is achieved, and the problem of drugs being unable to penetrate the blood-brain barrier is overcome. In addition, this technology can also be used to treat other diseases such as liver cancer, pancreatic cancer, thyroid cancer, breast cancer, kidney cancer, bone cancer, bladder cancer, and gallbladder cancer.

To provide methods for effectively treating and / or preventing cancer diseases.SOLUTION: The present invention provides a combination therapy comprising an anti-Claudin (CLDN) 18.2 antibody and an immune checkpoint inhibitor for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.SELECTED DRAWING: Figure 1

The invention relates to siRNA targeting TRIM29, the sequence of the siRNA is shown as SEQ ID NO.1. Through cell level and animal level experiment detection, the siRNA can inhibit expression of the TRIM29, and the sensitivity of gallbladder cancer to gemcitabine is remarkably improved; the invention further relates to gemcitabine and TRIM29 siRNA co-loaded lipid nanoparticles and a preparation method and application thereof, the preparation method comprises the steps that firstly, gemcitabine and TRIM29 siRNA wrapped lipid nanoparticles are constructed, then the gemcitabine and TRIM29 siRNA are co-incubated to obtain GSL, the GSL is oval in microcosmic shape and good in stability, through cell level and animal level experiment detection, the GSL has a good anti-tumor effect, and the GSL has a good anti-tumor effect on the gemcitabine and TRIM29 siRNA co-loaded lipid nanoparticles. The GSL can significantly reduce the protein expression level of TRIM29, significantly improve the sensitivity of gallbladder cancer to gemcitabine, inhibit tumor growth, and inhibit STAT3 pathway, and the GSL prepared by the method has good biological safety, and opens up a new channel for treatment of gallbladder cancer.

The invention belongs to the field of biological pharmacy, and particularly discloses application of evodiamine in inhibition of migration and invasion of gallbladder cancer cells and metastatic tumor growth. Aiming at the problems of poor drug targeting, high toxicity, easy drug resistance and the like in gallbladder cancer hepatic metastasis treatment, the invention provides various application forms of evodiamine: 1) an evodiamine single-drug sustained release preparation (PLGA or chitosan carrier) realizes long-acting sustained release through local intervention or intratumor injection; 2) the evodiamine liposome preparation (the ratio of DPPC to cholesterol is 3: 1, and the particle size is 80-150nm) can improve the enrichment rate of hepatic metastatic focus to 5.8% or above; (3) the evodiamine and chemotherapeutic drugs (oxaliplatin, 5-FU and the like) are combined to form a composition, and the synergy index is Cilt; 0.8, the toxicity of the system is obviously reduced; animal experiments show that the liver metastasis inhibition rate reaches 82.7% and the weight loss rate is only 10.5% when the liposome (3 mg / kg of evodiamine and 6 mg / kg of oxaliplatin) is combined, and a high-efficiency and low-toxicity solution is provided for gallbladder carcinoma metastasis.

The invention discloses a diazaspiro compound as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The diazaspiro compound is shown as a formula I, is a CCK-BR small-molecule agonist, has excellent agonistic activity, has good selectivity in CCK-AR and CCK-BR, can reduce side effects caused by off-target effects, and has no potential side effects such as cardiotoxicity. The molecules have potential treatment capacity on epilepsy, depression, dementia, anxiety, Alzheimer's disease, tinnitus, amblyopia, schizophrenia, neuropathic pain, memory loss, gastric acid, obesity, pancreatic cancer and gallbladder cancer.

The invention relates to the field of biological medicines, and discloses a targeted inhibitor capable of effectively inhibiting the progress of gallbladder cancer and remarkably improving the lifetime and prognosis of a patient. Through single-cell transcriptome data of a gallbladder cancer patient, single-cell transcriptome data of gallbladder cancer organoid, multiple immunofluorescence experiments, real-time quantitative PCR of gallbladder cancer cell lines, immunohistochemistry of gallbladder cancer tissues and organoid, gallbladder cancer whole exon data and inhibitor agonist experiments, it is found that compared with para-carcinoma, the single-cell transcriptome data of the gallbladder cancer patient, the single-cell transcriptome data of the gallbladder cancer organoid, the single-cell Differential genes of gallbladder cancer epithelial cells in cancer tissues are enriched to a WNT pathway, crosstalk is generated between the gallbladder cancer epithelial cells mainly through a WNT7A-FZD6 ligand and receptor pair in a WNT signal pathway, and inflammatory fibroblasts and epithelial cells can perform intercellular communication through a WNT5A-FZD6 ligand and receptor pair in an ncWNT signal pathway.

The invention relates to an application of an AhR-HEGBC-CYP1A1 regulation axis in preparation of a medicine for resisting gallbladder cancer. The invention provides application of shRNA of a specific interference AhR gene, shRNA of a specific interference HEGBC gene and / or shRNA of a specific interference CYP1A1 gene in preparation of drugs for targeted therapy of gallbladder carcinoma. It is found for the first time that proliferation, migration and invasion of gallbladder cancer cells can be effectively inhibited by inhibiting an AhR-HEGBC-CYP1A1 regulation axis through interference. According to the invention, sh-AhR, sh-HEGBC and sh-CYP1A1 which specifically knock down the mRNA expression levels of AhR, HEGBC and CYP1A1 are designed, the expression of an AhR-HEGBC-CYP1A1 regulation axis is interfered and inhibited by knocking down the mRNA expression levels of AhR, HEGBC and CYP1A1, and the proliferation, migration and invasion of gallbladder cancer cells are successfully inhibited, so that the AhR-HEGBC-CYP1A1 regulation axis can be used as a therapeutic target to prepare a drug for targeted therapy of gallbladder cancer.

The present invention provides a use of a MUC16c_del15Y polypeptide in preparing a drug for treating gallbladder cancer. The MUC16c_del15Y polypeptide competitively inhibits MUC16c in gallbladder cancer cells. The amino acid sequence of the MUC16c_del15Y polypeptide is shown in SEQ ID NO.1, and the amino acid sequence of MUC16c is shown in SEQ ID NO.2. Preparation of the polypeptide comprises: deleting the tyrosine site in wild-type MUC16c, synthesizing the polypeptide, and eluting and purifying. Compared with a control group, the MUC16c_del15Y polypeptide of the present invention inhibits the growth of gallbladder cancer xenografts in nude mice by 46%, demonstrating a significant inhibitory effect. MUC16c is an intracellular fragment of the MUC16 gene product and is similar in sequence to the MUC16c polypeptide. The MUC16c_del15Y polypeptide is rich in a high proportion of hydrophilic amino acids and is highly water-soluble.

The present invention provides antibodies useful as therapeutics for the treatment and / or prevention of diseases associated with cells expressing CLD18, including diseases associated with tumors such as stomach cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, liver cancer, head and neck cancer, and gallbladder cancer and their metastases.

The invention provides application of RAGE as an inhibition target in preparation of drugs for treating GBC, relates to the technical field of biomedicine, and finds a key action mechanism of DAMPs molecule HMGB1 in activation of RAGE receptors of GBC cells and promotion of PNI through in-depth research. Researches prove that HMGB1 released after neuronal necroptosis can specifically activate RAGE receptors on the surfaces of GBC cells, and then nerve invasion phenotypes of tumor cells are promoted. Based on the discovery, the invention provides an effective means for treating the GBC by using a small molecule RAGE inhibitor FPS-ZM1, and the inhibitor can effectively block the activation of an HMGB1-RAGE signal axis. A further research discovers that when the FPS-ZM1 is combined with the existing chemotherapeutic drug gemcitabine for use, the FPS-ZM1 shows a remarkable synergistic effect in the aspect of inhibiting tumor nerve invasion. The invention not only discloses an important role of an RAGE receptor in a GBC nerve invasion process, but also provides a clinical application scheme of a specific inhibitor FPS-ZM1 aiming at the target spot, and provides a new strategy and means for treating gallbladder cancer.

The invention provides an application of PLAC8 as a detection target in preparation of a tumor diagnosis product, and relates to the technical field of biomedicine, the technical key points are as follows: the application of the PLAC8 as the detection target in preparation of the tumor diagnosis product and a tumor prognosis condition inspection product integrates three gallbladder cancer clinical queues, and has the advantages of high accuracy, high sensitivity and high reliability. By combining a cross-species model and technologies of multiple immunofluorescence, single cell RNA sequencing and the like, the PLAC8 is found to be a cross-species conservative M2 macrophage gene with significant difference. PLAC8 is abnormally enriched in gallbladder cancer tissues, and normal gallbladder epithelium is almost not expressed and can be stably detected through tumor tissues and peripheral blood. Expression of the gene is limited to a macrophage cluster, the gene is in positive correlation with M2 markers CD206 and CD163, and M2 polarization is promoted by regulating cholesterol metabolism. Clinical verifications show that increase of PLAC8 + CD163 + macrophages in tumors is an independent prognosis factor, high expression is closely related to short lifetime of patients and increase of chemotherapy non-response rate, and PLAC8 can be used as a potential biomarker for evaluating drug resistance of gallbladder cancer chemotherapy and tumor progression.

It was found that SDF4 in a body fluid sample can be a marker for detecting a cancer patient with good sensitivity and specificity. By using a reagent for specifically detecting the SDF4, it is possible to detect gastric cancer, breast cancer, colorectal cancer, pancreatic cancer, esophageal cancer, hepatic cancer, liposarcoma, bladder cancer, brain tumor, head and neck cancer, gallbladder cancer, ovarian cancer, tongue cancer, or uterine cancer. The measurement of the SDF4 in the body fluid sample is a test method capable of detecting various types of cancer with a single test, and can be used for mass screening for cancer. Further, it is capable of detecting even cancer of an early stage with good sensitivity and specificity, and thus is capable of detecting cancer at an early stage to start a treatment.

The invention discloses an application of a compound as a CYP2E1 inhibitor, which is characterized in that the compound or a salt thereof as an inhibitor takes CYP2E1 as a target spot and is combined with the CYP2E1, and the CYP2E1 inhibitor has an inhibition effect on CYP2E1. The inhibitor can be used for preventing and treating tumors such as liver cancer, glioma, ovarian cancer, bladder cancer and gallbladder cancer. Similarly, the inhibitor can also be used for preventing and treating other inflammation-related diseases such as liver injury, fatty liver, hepatitis, hepatic fibrosis, rheumatic and rheumatoid arthritis, sepsis, Alzheimer's disease, ischemic cerebral apoplexy, Parkinson's disease, hyperlipidemia, atherosclerosis, coronary heart disease, diabetes mellitus and the like.

The invention relates to the field of biological medicines, and discloses a preparation method and application of a neutralizing antibody capable of effectively inhibiting dryness of gallbladder cancer cells and progress of gallbladder cancer and remarkably improving the lifetime and prognosis of a patient. A gene sequence for coding the humanized anti-FZD6 monoclonal neutralizing antibody comprises a sequence of a heavy chain variable region and a sequence of a light chain variable region. The gene sequence of the heavy chain variable region is as shown in SEQ ID NO: 1, and the gene sequence of the light chain variable region is as shown in SEQ ID NO: 2. The neutralizing antibody targets a non-classical Wnt pathway receptor FZD6, so that the activation of a Wnt / Ca < 2 + > signal pathway can be effectively inhibited, and the migration and growth of gallbladder tumor cells can be inhibited. Experimental detection proves that the FZD6 neutralizing antibody can effectively block the interaction between Wnt5a-FZD6-mediated tumor-related fibroblasts and gallbladder cancer cells, remodel the gallbladder cancer immunosuppressive tumor microenvironment and inhibit the dryness of gallbladder tumor cells and the migration and growth of gallbladder cancer cells, and can be applied to preparation of gallbladder cancer specific targeting drugs.

The present invention provides the use of TBRG4 as a drug target in in vitro screening for drugs for the treatment of gallbladder cancer, wherein the drug is a drug that inhibits TBRG4 expression. The present invention also provides the use of a reagent for detecting TBRG4 in the preparation of a kit for diagnosing gallbladder cancer. The research results of the present invention found that inhibiting TBRG4 can significantly inhibit the proliferation, migration and invasion of gallbladder cancer cells, suggesting that TBRG4 is an important regulatory molecule affecting the progression of gallbladder cancer. Further studies have shown that the U2AF2 / TBRG4 / EGFR signaling pathway can regulate the glycolysis process of gallbladder cancer cells through the PI3K / AKT pathway. Inhibiting TBRG4 can significantly inhibit the glycolysis of gallbladder cancer cells, thereby confirming that TBRG4 is an important energy metabolism regulatory molecule, opening up a new therapeutic approach for the treatment of gallbladder cancer.

The invention relates to an application of an AhR-HEGBC-CYP1A1 regulation axis in preparation of a medicine for resisting gallbladder cancer. The invention provides application of shRNA of a specific interference AhR gene, shRNA of a specific interference HEGBC gene and / or shRNA of a specific interference CYP1A1 gene in preparation of drugs for targeted therapy of gallbladder carcinoma. It is found for the first time that proliferation, migration and invasion of gallbladder cancer cells can be effectively inhibited by inhibiting an AhR-HEGBC-CYP1A1 regulation axis through interference. According to the invention, sh-AhR, sh-HEGBC and sh-CYP1A1 which specifically knock down the expression levels of AhR, HEGBC and CYP1A1mRNA are designed, the expression of an AhR-HEGBC-CYP1A1 regulatory axis is interfered and inhibited by knocking down the expression levels of AhR, HEGBC and CYP1A1mRNA, and the proliferation, migration and invasion of gallbladder cancer cells are successfully inhibited, so that the AhR-HEGBC-CYP1A1 regulatory axis can be used as a therapeutic target to prepare a drug for targeted therapy of gallbladder cancer.

Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and / or preventing diseases associated with cells expressing claudin18.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 / PD-L1 monoclonal antibodies), and / or by combination therapies where the anti-claudin18.2 antibodies are administered before, after, or concurrently with chemotherapy.